HomeCompareRDTCF vs JNJ

RDTCF vs JNJ: Dividend Comparison 2026

RDTCF yields 2222.22% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RDTCF wins by $26607504688.23M in total portfolio value
10 years
RDTCF
RDTCF
● Live price
2222.22%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26607504688.26M
Annual income
$24,443,703,761,807,280.00
Full RDTCF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RDTCF vs JNJ

📍 RDTCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRDTCFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RDTCF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RDTCF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RDTCF
Annual income on $10K today (after 15% tax)
$188,888.89/yr
After 10yr DRIP, annual income (after tax)
$20,777,148,197,536,188.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, RDTCF beats the other by $20,777,148,197,532,204.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RDTCF + JNJ for your $10,000?

RDTCF: 50%JNJ: 50%
100% JNJ50/50100% RDTCF
Portfolio after 10yr
$13303752344.14M
Annual income
$12,221,851,880,905,984.00/yr
Blended yield
91.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RDTCF
No analyst data
Altman Z
-20.8
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RDTCF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRDTCFJNJ
Forward yield2222.22%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$26607504688.26M$30.3K
Annual income after 10y$24,443,703,761,807,280.00$4,689.40
Total dividends collected$26455115546.17M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RDTCF vs JNJ ($10,000, DRIP)

YearRDTCF PortfolioRDTCF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$232,922$222,222.22$10,592$272.30+$222.3KRDTCF
2$5,086,656$4,837,429.33$11,289$357.73+$5.08MRDTCF
3$104,173,443$98,730,720.93$12,123$472.89+$104.16MRDTCF
4$2,001,166,924$1,889,701,340.37$13,141$629.86+$2001.15MRDTCF
5$36,067,485,611$33,926,237,001.88$14,408$846.81+$36067.47MRDTCF
6$610,050,404,477$571,458,194,873.63$16,021$1,151.60+$610050.39MRDTCF
7$9,686,139,336,337$9,033,385,403,546.24$18,122$1,588.22+$9686139.32MRDTCF
8$144,409,519,569,037$134,045,350,479,156.38$20,930$2,228.20+$144409519.55MRDTCF
9$2,022,243,856,495,371$1,867,725,670,556,501.50$24,792$3,191.91+$2022243856.47MRDTCF
10$26,607,504,688,257,330$24,443,703,761,807,280.00$30,274$4,689.40+$26607504688.23MRDTCF

RDTCF vs JNJ: Complete Analysis 2026

RDTCFStock

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.

Full RDTCF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RDTCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RDTCF vs SCHDRDTCF vs JEPIRDTCF vs ORDTCF vs KORDTCF vs MAINRDTCF vs ABBVRDTCF vs MRKRDTCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.